DRL sells brand Sernivo; grants Promiseb and Trianex US marketing rights to Encore Dermatology
Posted on03 Apr 2019
Comments0
Dr. Reddy’s Laboratories Limited through its wholly owned subsidiary Promius Pharma, LLC, announces the sale of its rights for Sernivo (betamethasone dipropionate)... Read More
Check Your Competency in Data Integrity
Data Integrity refers to maintaining and assuring the accuracy and consistency of data over its entire product life-cycle. Over the last few years several, FDA... Read More
Lilly, ImmuNext licensing deal for R&D collaboration
Eli Lilly and Company and ImmuNext, Inc. announced a global licensing and research collaboration focused on the study of a preclinical novel... Read More
GSK’s Advair Loss of Exclusivity (LOE) and Mylan’s Wixela Inhub generic entry
Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the GlaxoSmithKline’s respiratory blockbuster, Advair. ... Read More
Roche to acquire U.S.-Based Gene Therapy Specialist Spark @ $4.8 Billion
Swiss drugmaker Roche agreed to buy Philadelphia-based Spark Therapeutics for $4.8 billion. Spark works to create gene therapies for genetic diseases, including... Read More
Novartis licenses lipoprotein-lowering CVD drug AKCEA-APO(a)-LRx
Posted on26 Feb 2019
Comments0
Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ AKCEA-APO(a)-LRx, a treatment to reduce the risk... Read More
Merck to acquire immunotherapy company, Immune Design for US$ 300 million
Merck and Immune Design announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire... Read More
GSK’s disinvestment of Chiron Behring to Bharat Biotech
Posted on16 Feb 2019
Tagsacquisition in pharma, Bharat Biotech, Chiron Behring Vaccines, disinvestment in pharma business, GSK, Hoechst AG
Comments0
Bharat Biotech’s recent plans to acquire Chiron Behring Vaccine Private Limited from GlaxoSmithKline Asia, is expected to boost the company’s rabies vaccine... Read More
Recordati received exclusive rights to commercialize Juxtapid in Japan from Aegerion Pharmaceuticals
Posted on07 Feb 2019
TagsAegerion, HoFH, Juxtapid, Novelion Therapeutics, orphan drug, orphan drug designation, rare disease
Comments0
Recordati announces the signing of a license agreement with Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics Inc., for the exclusive rights... Read More
Glenmark Specialty S.A’s exclusive licensing agreement with Grandpharma (China) Co. Ltd for commercializing Ryaltris in China
Posted on07 Feb 2019
TagsGlemark outlicensing, global pharma licensing deal, licensing deal in pharma, outlicensing in pharma
Comments0
Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, announced that its Swiss subsidiary, Glenmark Specialty S.A, has entered into an exclusive... Read More